HISTOACRYL® Used for Embolization of Thoracoabdominal Artery Bleeding
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAesculap AG
About this trial
This observational study will collect information from adult patients in Japan who are treated with Histoacryl® to stop bleeding from arteries in the chest or abdomen, in order to better understand how well the treatment works and how safe it is during routine medical care.
Eligibility criteria
Qualifiers
Active thoracoabdominal arterial bleeding diagnosed by endoscopy, catheter angiography, or computed tomography angiography (CTA).
Planned embolization treatment using Histoacryl® as the sole embolic agent for the target lesion.
No endoleak following thoracic endovascular aortic repair (TEVAR) or endovascular abdominal aortic repair (EVAR).
Patients with malignant tumors must have an expected survival of at least 1 month.
Disqualifiers
Previous embolization in the target vascular territory.
Known allergy or hypersensitivity to n-butyl cyanoacrylate (NBCA), Lipiodol®, or related treatment components.
Use of adjunctive embolic agents in the same target location.
Planned surgical treatment after embolization as part of a predefined two-step treatment strategy.
Trial design
Treatments tested in this trial
- Embolization therapy
Treatment groups
176 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov